The significance of HLA DRB1*1501 and oligoclonal bands in multiple sclerosis: Clinical features and disability

Medicina

Volumn 47, Issue 7, 2011, Pages 368-373

  Balnyte, Renata ^a   Rastenyte, Daiva ^a   Uloziene, Ingrida ^a   Mickevičiene, Dalia ^a   Skordeniene, Erika ^a   Vitkauskiene, Astra ^a  

^a LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

Author keywords

Clinical features; Disability; Human leukocyte antigen DRB1*1501; Multiple sclerosis; Oligoclonal bands

Indexed keywords

EID: 84856669613     PISSN: 1010660X     EISSN: None     Source Type: Journal    
DOI: 10.3390/medicina47070052     Document Type: Article

References (33)

1. Wu JS, Qui W, Castley A, James I, Joseph J, Christiansen FT, et al. Presence of CSF oligoclonal bands is associated with the HLA-DRB1 genotype in a West Australian multiple sclerosis cohort. J Neurol Sci 2010;288:63-7
2. Bennett JL. Multiple sclerosis pathophysiology update. Adv Stud Pharm 2009;3:58-62
3. Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010;9:A387-94
4. Pirko I, Noseworthy JH. Demyelinating disorders of the central nervous system. In: Goetz CG, editor. Textbook of clinical neurology. 3rd ed. Philadelphia, PA: Saunders Elsevier; 2007. p. 1103-35
5. Schmidt H, Williamson D, Ashley-Koch A. HLA-DR15 haplotype and multiple sclerosis: a HuGe review. Am J Epidemiol 2007;165:1097-109
6. Imrell K, Greiner E, Hillert J, Mastermann T. HLADRB1* 15 and cerebrospinal-fl uid-specifi c oligoclonal immunoglobulin G bands lower age at attainment of important disease milestones in multiple sclerosis. J Neuroimmunol 2009;210:128-30
7. DeLuca GC, Ramagopalan SV, Herrera BM, Dyment DA, Lincoln MR, Montpetit A, et al. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Natl Acad Sci U S A 2007;52:20896-901
8. Okuda DT, Srinivasan R, Oksenberg JR, Goodin DS, Baranzini SE, Beheshtian A, et al. Genotype-phenotype correlations in multiple sclerosis: HLA genes infl uence disease severity inferred by HMR spectroscopy and MRI measures. Brain 2009;132:250-9
9. Masterman T, Ligers A, Olsson T, Andersson M, Olerup O, Hillert J. HLA-DR 15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 2000;48:211-9
10. Weatherby SJ, Thomson W, Pepper L, Donn R, Worthington J, Mann CL, et al. HLA DRB1 and disease outcome in multiple sclerosis. J Neurol 2001;248:304-10
11. Hensiek AE, Sawcer SJ, Feakes R, Deans J, Mander A, Akesson E, et al. HLA-DR15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J Neurol Neurosurg Psychiatry 2002;72:184-7
12. Idiman E, Ozakbas S, Dogan Y, Kosehasanogullari G. The signifi cance of oligoclonal bands in multiple sclerosis: relevance of demographic and clinical features, and immunogenetic backgrounds. J Neuroimmunol 2009;212:121-4
13. Villar LM, Masterman T, Casanova B, Gomez-Rial J, Espino M, Sadaba MC, et al. CSF oligoclonal band patterns reveal disease heterogeneity in multiple sclerosis. J Neuroimmunol 2009;211:101-4
14. Siritho S, Freedman MS. The prognostic signifi cance of cerebrospinal fl uid in multiple sclerosis. J Neurol Sci 2009; 279:21-5
15. Koch M, Heersema D, Mostert J, Teelken A, De Keyser J. Cerebrospinal fl uid oligoclonal bands and progression of disability in multiple sclerosis. Eur J Neurol 2007;14:797-800
16. World Health Organization, Multiple Sclerosis International Federation. Atlas multiple sclerosis resources in the world 2008. Geneva: World Health Organization; 2008. Available from: URL: www.who.int/entity/mental_health/neurology/Atlas_MS_WEB.pdf
17. Polman CH, Reingold SC, Edan G. Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald criteria. Ann Neurol 2005;6:840-6
18. Celesia GG, Brigell MG. Recommended standards for pattern electroretinograms and visual evoked potentials. In: Deuschl G, Eisen A, editors. Recommendations for the practice of clinical neurophysiology: guidelines of the International Federation of Clinical Physiology (EEG, suppl 52). Elsevier Science; 1999
19. Freedman MS, Thompson EJ, Deisenhammer F, Giovannoni G, Grimsley G, Keir G, et al. Recommended standard of cerebrospinal fl uid analysis in the diagnosis of multiple sclerosis. Arch Neurol 2005;62:865-70
20. Skrodenienė E, Marčiulionytė D, Padaiga Ž, Jašinskienė, Sadauskaitė-Kuehne V, Sanjeevi CB, et al. HLA class II alleles and haplotypes in Lithuanian children with type I diabetes and healthy children (HLA and type I diabetes). Medicina (Kaunas) 2010;8:505-10
21. Link H, Huang YM. Oligoclonal bands in multiple sclerosis cerebrospinal fl uid: an update on methodology and clinical usefulness. J Neuroimmunol 2006;180:17-28
22. Romero-Pinel L, Yelamos-Martinez S, Bau L, Matas E, Guberias L, Maria Pujai J, et al. Association of HLA DRB1*15 allele and CSF oligoclonal bands in a Spanish multiple sclerosis cohort. Eur J Neurol 2011;18(10):1258-62
23. Nakashima I, Fujihara K, Misu T, Fujimori J, Sato S, Takase S, et al. Comparative study of Japanese multiple sclerosis patients with and without oligoclonal IgG bands. Mult Scler 2002;8:459-62
24. Diniz da Gama P, Machado LR, Livramento JA, Gomes HR, Adoni T, Martins Lino AM, et al. Study of oligoclonal bands restricted to the cerebrospinal fl uid in multiple sclerosis patients in the city of Sao Paulo. Arq Neuropsiquiatr 2009;4:1017-22
25. Awad A, Hemmer B, Hartung PH, Kieseier B, Bennett JL, Stuve O. Analysis of cerebrospinal fl uid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol 2010; 219:1-7
26. Sa MJ, Sequera L, Rio ME, Thompson EJ. Oligoclonal IgG bands in the CSF of Portuguese patients with MS. Arq Neuropsiquiatr 2005;63:375-9
27. Amato MP, Ponziani G. A prospective study on the prognosis of multiple sclerosis. J Neurol Sci 2000;21:S831-8
28. Huttner HB, Schellinger PD, Struffert T, Ricter G, Engelhorn T, Bassemir T, et al. MRI criteria in MS patients with negative and positive oligoclonal bands: equal fulfi llment of Barkhof 's criteria but different lesion patterns. J Neurol 2009;256:1121-5
29. Oksenberg JR, Baranzini SE. Multiple sclerosis genetics: is the glass half empty or half full? Nat Rev Neurol 2010; 6:429-37
30. Celius EG, Harbo HF, Egeland T, Vartdal F, Vandvik K, Spurkiand A. Sex and age at diagnosis are correlated with HLA-DR2, DQ6 haplotype in multiple sclerosis. J Neurol Sci 2000;178:132-5
31. Smestad C, Brynedal B, Jonasdottir G, Lorentzen AR, Masterman T, Akesson E, et al. The impact of the HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients. Eur J Neurol 2007; 14:835-40
32. McDonell GV, Mawhinney H, Graham CA, Hawkins SA, Middleton D. A study of the HLA-DR region in clinical subgroups of multiple sclerosis and its infl uence on prognosis. J Neurol Sci 1999;165:77-83
33. Weinsheker BG, Santrach P, Bissonet AS, McDonell SK, Shaid D, Moore SB, et al. Major histocompatibility complex class II alleles and the course and outcome of MS: a population-based study. Neurology 1998;51:742-7.